How Long Can You Live With Cancer in Your Spine?

Survival with cancer in the spine ranges from weeks to decades, and the single biggest factor is whether the tumor started there or spread from somewhere else. Most spinal cancers are metastatic, meaning a cancer elsewhere in the body sent cells to the vertebrae or spinal cord. For those cases, median survival after surgery hovers around six to seven months in acute presentations, but people with slower-growing primary cancers like breast or thyroid tumors can live years. Primary spinal tumors that originate in the spine itself are far rarer and often carry much better outlooks, with five-year survival above 80% in some types.

Primary Spinal Tumors Are a Different Story

Cancers that begin in the spinal cord or vertebral column itself account for a small fraction of all spinal cancers. A population-based analysis found that the five-year relative survival for patients with malignant primary spinal cord tumors was about 86%, with those diagnosed with ependymoma faring even better than other subtypes.¹ That figure is strikingly high compared to metastatic disease and reflects the fact that many primary spinal tumors grow slowly and can be treated surgically.

Chordoma is one of the more well-known primary spinal tumors. It grows from leftover embryonic tissue in the spine or skull base and tends to recur locally rather than spread widely. In a multicenter study of cervical spine chordomas, five-year and ten-year survival rates were about 82% and 53%, though nearly half of patients experienced local recurrence.² Chordomas at different spinal levels behave somewhat differently. One study found five-year and ten-year survival rates of 80% for mobile spine chordomas and 78% and 48% for sacral chordomas.³ These tumors can be managed for years, and their slow growth is sometimes described as indolent, though recurrence remains the persistent challenge.⁴

When Cancer Spreads to the Spine

Metastatic spinal disease is overwhelmingly more common than primary spinal tumors. The spine is one of the most frequent destinations for cancer cells traveling through the bloodstream, partly because vertebral bone is richly supplied with blood. Lung, breast, prostate, kidney, and thyroid cancers are among the most common sources.

The type of primary cancer is the single strongest predictor of how long someone will live after spinal metastases are found. A Canadian population-based study of patients who underwent surgery for spinal metastases found that half of patients with melanoma, upper gastrointestinal cancer, or lung cancer died within 90 days. By contrast, median survival was roughly two and a half years for thyroid cancer, about two years for myeloma, and nearly two years for breast cancer.⁵ A Finnish national registry study confirmed the pattern: one-year survival after surgery was about 75% for breast cancer but closer to 45–47% for kidney and prostate cancers.⁶

These numbers reflect patients who were well enough for surgery, which already selects for people in better overall condition. Many patients with spinal metastases are not surgical candidates, and their survival tends to be shorter. A randomized trial of patients receiving radiation for spinal metastases found a median overall survival of about seven months, with the type of primary cancer and the patient’s functional status being the strongest predictors.⁷

Why Physical Function Matters So Much

Doctors repeatedly find that how well a person functions day to day is one of the strongest signals of how long they will survive with spinal metastases. Performance status is typically measured on scales that assess things like whether you can walk, care for yourself, and carry on normal activities. The Karnofsky Performance Status scale runs from 0 to 100, with higher scores meaning better function.

In a study of patients who had surgery for spinal metastases, both common performance scales were linked to 90-day survival, though neither was a crystal ball on its own. The most balanced accuracy came at a Karnofsky score of 70 or above, where sensitivity and specificity were both in the low-to-mid 60s percent.⁸ Another study identified preoperative performance status and whether a patient could walk after surgery as independent predictors of longer survival.⁹

The practical takeaway is that maintaining mobility and independence is not just about quality of life. It genuinely correlates with living longer. This is part of why doctors push so hard to preserve or restore walking ability when spinal cancer threatens the spinal cord.

Oligometastatic Versus Widespread Disease

The number of metastases matters. Patients with only a few metastatic sites, a state called oligometastatic disease, tend to live longer than those with cancer that has spread widely. A multicenter international study found a clear survival advantage for oligometastatic patients compared to those with widespread spinal involvement: about 77% were alive at six months versus 65% for the polymetastatic group. This advantage held whether patients were treated with radiation alone or with surgery.¹⁰

For patients with a single spinal metastasis and no other sites of spread, some clinicians pursue aggressive local treatment with the goal of long-term control or even cure. One case report described a patient with oligometastatic spinal disease who underwent separation surgery with carbon-fiber implants followed by stereotactic radiation. Her spinal disease remained controlled for three years, though she ultimately died from brain metastases.¹¹ That pattern, where spinal disease is controlled but other sites progress, underscores that survival with spinal metastases is driven by the whole-body cancer picture, not just what happens in the spine itself.

Spinal Cord Compression Changes the Urgency

When a spinal tumor grows large enough to press on the spinal cord, the situation becomes urgent. Metastatic spinal cord compression can cause progressive weakness, numbness, and loss of bladder or bowel control. How quickly symptoms develop and how fast treatment is started both affect survival and the likelihood of recovering function.

A study of patients with metastatic spinal cord compression from lung cancer found that those whose motor deficits developed within 10 days or fewer had worse overall survival than those with slower onset, suggesting rapid neurological decline reflects more aggressive disease.¹² On the treatment side, patients who could still walk before surgery survived longer than those who had already lost motor function. Among those who had lost function, surgery within seven days of the onset of weakness led to better survival than delayed surgery, and those who were able to walk again after the operation did better still.¹³

For patients with very short life expectancies, radiation therapy for spinal cord compression tends to stabilize function rather than restore it. One study found that most patients’ motor and bladder function stayed about the same after radiation, neither improving dramatically nor worsening significantly.¹⁴ The goal in these cases shifts from cure to comfort and preservation of whatever function remains.

What Surgery Can and Cannot Do

Surgery for spinal metastases is almost never curative. Its goals are to relieve pressure on the spinal cord, stabilize the spine, reduce pain, and maintain the ability to walk. A study tracking quality of life after surgery for spinal metastases found that walking ability, pain, and overall functional status all improved significantly after surgery and stayed improved through at least a year of follow-up.¹⁵

In emergent situations where patients present acutely with rapid neurological deterioration, outcomes are understandably worse. A study of patients who needed emergency decompression surgery for acutely presenting spinal metastases found a median survival of about six and a half months.¹⁶ That is shorter than the survival seen in patients who undergo planned surgery, which reinforces the idea that earlier detection and treatment generally lead to better outcomes.

For patients whose main problem is a collapsed vertebra causing severe pain rather than spinal cord compression, vertebroplasty or kyphoplasty can help. These are minimally invasive procedures where bone cement is injected into a fractured vertebra to stabilize it and reduce pain.¹⁷ In patients with myeloma-related vertebral fractures, one study found pain dropped by an average of nearly five points on a ten-point scale, and that relief lasted for years in the patients who were followed long-term.¹⁸

Radiation and the Rise of Stereotactic Techniques

Conventional radiation has long been a mainstay for treating spinal metastases, particularly for pain control and to slow tumor growth. In recent years, stereotactic body radiation therapy has become increasingly important. SBRT delivers high doses of radiation to a precisely targeted area while limiting damage to surrounding tissue, including the spinal cord itself.

A study of SBRT for spine metastases found a one-year local control rate of 88% and a one-year overall survival rate of 64%.¹⁹ The combination of SBRT with immunotherapy is also being explored. When immunotherapy was given after SBRT rather than before, median overall survival was dramatically different: about 32 months versus roughly seven months, though the study noted that performance status also played a role.²⁰ The broader trend is toward combining local spine treatments with systemic therapies like targeted drugs and immunotherapy, which are improving survival across many cancer types.²¹

Recurrence after initial treatment is common. As patients live longer thanks to better systemic therapies, the problem of disease coming back at a previously treated spinal site grows more relevant. Managing recurrent spinal metastases can involve repeat radiation, re-operation, or both, with the overarching goals of controlling pain, preserving neurological function, preventing instability, and maintaining independence.

How Doctors Try to Predict Survival

Several scoring systems exist to help doctors estimate how long a patient with spinal metastases is likely to live. The most widely used is the Tokuhashi score, which factors in things like the type of primary cancer, whether internal organs are also affected, and the patient’s functional status. These estimates matter because they guide treatment decisions: a patient expected to live more than a year might benefit from aggressive surgery, while someone with weeks to live may be better served by radiation or comfort care alone.

The problem is that these scoring systems are only modestly accurate. One study found the revised Tokuhashi score’s predictive value for survival time was about 66%, and while it could distinguish between better and worse prognosis groups, it was far from precise for individual patients.²² A head-to-head comparison of multiple scoring systems found that some performed better than others, but none was consistently reliable. The Tokuhashi score had the highest area-under-the-curve measurement, while the Tomita score performed the worst.²³ Researchers have also found that many of these systems tend to underestimate how long patients actually live, which could lead to under-treatment.

Newer machine-learning approaches are being developed to improve predictions. These algorithms can incorporate more variables and detect patterns that simpler scoring tools miss. One study found that machine-learning models using algorithms like XGBoost, with preoperative blood albumin levels as a key input, showed promise for predicting 90-day, 180-day, and one-year survival.²⁴ However, when 12 prediction models, including two machine-learning tools, were externally validated on a separate patient population, most yielded only fair accuracy, with the Revised Katagiri scoring system outperforming many of the alternatives.²⁵ Prediction remains a challenge, and doctors typically treat these scores as one input among many rather than a definitive forecast.

Socioeconomic Factors That Shouldn’t Matter but Do

Where you live and what resources you have access to can shape outcomes with spinal metastases in ways that have nothing to do with the biology of the cancer. A study found that patients in the lowest socioeconomic neighborhoods survived shorter and spent fewer days at home compared to those in the most advantaged areas. Part of this gap was explained by differences in the types of primary cancers and overall frailty, but access to care played a role too: patients in lower socioeconomic neighborhoods were less likely to receive stereotactic radiation, had later initiation of palliative care, and lived farther from cancer centers.²⁶

Another study found that living in a zip code with lower educational attainment was associated with longer hospital stays, and that demographic factors like race and sex were linked to complication rates after treatment for spinal metastases.²⁷ Interestingly, when researchers looked specifically at patients who actually received SBRT, they found no significant differences in local control or overall survival based on race, insurance type, or area deprivation. One-year survival was around 55–56% regardless of socioeconomic group.²⁸ The disparity, in other words, appears to be about who gets advanced treatment in the first place rather than how well the treatment works once delivered. Getting to the right center and receiving the right therapy on time can matter as much as the cancer’s biology.